Ticker

NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and…

SG Americas Securities LLC reduced its holdings in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 51.5% in the undefined quarter, according to the company in its most recent filing with the SEC. The firm owned 19,997 shares of the company's stock after selling 21,249 shares during the quarter. SG Americas Securities LLC's holdings in

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis Results further support the differentiated profile of ICOTYDE, the first and only IL-23 receptor targeted oral peptide NEWARK, CA / ACCESS Newswire / March 28, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or…

Protagonist Therapeutics earns a Buy rating, driven by Icotyde's FDA approval and robust near-term commercialization catalysts. Icotyde, the first oral IL-23 receptor antagonist for plaque psoriasis, offers best-in-class oral efficacy and placebo-like safety, with significant royalty and milestone potential. PTGX's pipeline, validated by Icotyde and Rusfertide, leverages its proprietary Vectrix platform to target…

Protagonist Therapeutics (NASDAQ: PTGX) executives said March 18 that the U.S. Food and Drug Administration has approved ICOTYDE for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kilograms and are candidates for systemic therapy or phototherapy. On the company's conference call, President